CN102038700B - 掩盖苦味的含环酯红霉素的口服组合物 - Google Patents
掩盖苦味的含环酯红霉素的口服组合物 Download PDFInfo
- Publication number
- CN102038700B CN102038700B CN200910206556A CN200910206556A CN102038700B CN 102038700 B CN102038700 B CN 102038700B CN 200910206556 A CN200910206556 A CN 200910206556A CN 200910206556 A CN200910206556 A CN 200910206556A CN 102038700 B CN102038700 B CN 102038700B
- Authority
- CN
- China
- Prior art keywords
- orally administered
- erythromycin
- surfactant
- suspending agent
- adsorbent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 20
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims abstract description 84
- 229960003276 erythromycin Drugs 0.000 claims abstract description 42
- 239000000375 suspending agent Substances 0.000 claims abstract description 20
- 235000000346 sugar Nutrition 0.000 claims abstract description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000004094 surface-active agent Substances 0.000 claims abstract description 11
- 239000000945 filler Substances 0.000 claims abstract description 10
- 125000004122 cyclic group Chemical group 0.000 claims description 38
- 150000002148 esters Chemical class 0.000 claims description 38
- 150000008163 sugars Chemical class 0.000 claims description 17
- 239000000725 suspension Substances 0.000 claims description 17
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical group [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 13
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 13
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 12
- WBZFUFAFFUEMEI-UHFFFAOYSA-M Acesulfame k Chemical compound [K+].CC1=CC(=O)[N-]S(=O)(=O)O1 WBZFUFAFFUEMEI-UHFFFAOYSA-M 0.000 claims description 10
- 235000010358 acesulfame potassium Nutrition 0.000 claims description 10
- 229960004998 acesulfame potassium Drugs 0.000 claims description 10
- 239000000619 acesulfame-K Substances 0.000 claims description 10
- 239000003463 adsorbent Substances 0.000 claims description 10
- 239000002552 dosage form Substances 0.000 claims description 10
- 229930006000 Sucrose Natural products 0.000 claims description 9
- 239000005720 sucrose Substances 0.000 claims description 9
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 8
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 8
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 8
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 7
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 7
- 229950005770 hyprolose Drugs 0.000 claims description 7
- 239000008101 lactose Substances 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- 235000010355 mannitol Nutrition 0.000 claims description 7
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 6
- 239000003795 chemical substances by application Substances 0.000 claims description 6
- 238000012856 packing Methods 0.000 claims description 6
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 claims description 5
- 108010011485 Aspartame Proteins 0.000 claims description 5
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 claims description 5
- 239000004376 Sucralose Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 239000000605 aspartame Substances 0.000 claims description 5
- 235000010357 aspartame Nutrition 0.000 claims description 5
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 claims description 5
- 229960003438 aspartame Drugs 0.000 claims description 5
- 229940109275 cyclamate Drugs 0.000 claims description 5
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 5
- 229940085605 saccharin sodium Drugs 0.000 claims description 5
- 235000019408 sucralose Nutrition 0.000 claims description 5
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims description 5
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 4
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 claims description 4
- 229910000287 alkaline earth metal oxide Inorganic materials 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 4
- 229920000053 polysorbate 80 Polymers 0.000 claims description 4
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 4
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 238000003556 assay Methods 0.000 claims description 3
- 239000011230 binding agent Substances 0.000 claims description 3
- 239000000395 magnesium oxide Substances 0.000 claims description 3
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 claims description 3
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 238000005303 weighing Methods 0.000 claims description 3
- 125000000185 sucrose group Chemical group 0.000 claims 1
- 238000002360 preparation method Methods 0.000 abstract description 14
- 230000002745 absorbent Effects 0.000 abstract 1
- 239000002250 absorbent Substances 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 18
- 239000003814 drug Substances 0.000 description 14
- 235000019658 bitter taste Nutrition 0.000 description 10
- 239000002904 solvent Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000004090 dissolution Methods 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000002496 gastric effect Effects 0.000 description 4
- 238000005286 illumination Methods 0.000 description 4
- 238000007689 inspection Methods 0.000 description 4
- 239000003120 macrolide antibiotic agent Substances 0.000 description 4
- 238000005070 sampling Methods 0.000 description 4
- 238000012216 screening Methods 0.000 description 4
- 238000001035 drying Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 229960002626 clarithromycin Drugs 0.000 description 2
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 2
- 235000012141 vanillin Nutrition 0.000 description 2
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical group CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 231100001048 fetal toxicity Toxicity 0.000 description 1
- 238000005189 flocculation Methods 0.000 description 1
- 230000016615 flocculation Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000031891 intestinal absorption Effects 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 235000012245 magnesium oxide Nutrition 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (8)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910206556A CN102038700B (zh) | 2009-10-14 | 2009-10-14 | 掩盖苦味的含环酯红霉素的口服组合物 |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN200910206556A CN102038700B (zh) | 2009-10-14 | 2009-10-14 | 掩盖苦味的含环酯红霉素的口服组合物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN102038700A CN102038700A (zh) | 2011-05-04 |
| CN102038700B true CN102038700B (zh) | 2012-09-12 |
Family
ID=43905464
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN200910206556A Active CN102038700B (zh) | 2009-10-14 | 2009-10-14 | 掩盖苦味的含环酯红霉素的口服组合物 |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102038700B (zh) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103099807A (zh) * | 2011-11-15 | 2013-05-15 | 海南澳美华制药有限公司 | 一种掩盖苦味和增加布洛芬溶出度的复方锌布口服组合物 |
| CN104688757A (zh) * | 2013-12-09 | 2015-06-10 | 海南澳美华制药有限公司 | 一种增加溶出度的环酯红霉素的口服组合物 |
| US20190336476A1 (en) * | 2016-12-28 | 2019-11-07 | Fujifilm Toyama Chemical Co., Ltd. | Pharmaceutical composition |
| CN113679685B (zh) * | 2021-08-27 | 2022-10-14 | 澳美制药(苏州)有限公司 | 环酯红霉素片剂的制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631371A (zh) * | 2004-12-20 | 2005-06-29 | 李�杰 | 口服无苦味的大环内酯类抗生素散剂及其处方和制备方法 |
| CN1660872A (zh) * | 2005-01-02 | 2005-08-31 | 李�杰 | 新的新型大环内酯类抗生素2-位羟基酯和其制剂及其制备方法 |
-
2009
- 2009-10-14 CN CN200910206556A patent/CN102038700B/zh active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1631371A (zh) * | 2004-12-20 | 2005-06-29 | 李�杰 | 口服无苦味的大环内酯类抗生素散剂及其处方和制备方法 |
| CN1660872A (zh) * | 2005-01-02 | 2005-08-31 | 李�杰 | 新的新型大环内酯类抗生素2-位羟基酯和其制剂及其制备方法 |
Non-Patent Citations (1)
| Title |
|---|
| 王妤.环酯红霉素干混悬剂微生物限度检查方法的建立.《广东药学院学报》.2007,第23卷(第6期),p.665- 666. * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN102038700A (zh) | 2011-05-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102038700B (zh) | 掩盖苦味的含环酯红霉素的口服组合物 | |
| CN108295101B (zh) | 一种可用于治疗痛风及高尿酸疾病的碱性泡腾片 | |
| CN102286045B (zh) | 罗红霉素一水合物结晶、其制备方法及含该结晶和盐酸氨溴索组合的组合物干混悬剂 | |
| CN101411715A (zh) | 含有阿卡波糖的药物组合物 | |
| CN101862333B (zh) | 左亚叶酸钠稳定的口服制剂及其制备方法 | |
| CN103524533A (zh) | 一种头孢丙烯化合物、其分散片、干混悬剂及制备方法 | |
| CN105749154A (zh) | 一种治疗肝癌的益生菌发酵中药复方组合物及其制备和检测方法 | |
| CN106361689A (zh) | 一种福多司坦口服溶液及其制备方法 | |
| CN110881555A (zh) | 一种具有双降作用的分散糖果片 | |
| CN102688251B (zh) | 西甲硅油组合物 | |
| CN102068464B (zh) | 六神曲抗菌、抗病毒有效部位提取物及其医药用途 | |
| CN104000797A (zh) | 一种含芒果苷类化合物的药物制剂及其制备方法 | |
| CN102755287A (zh) | 阿奇霉素口服液及其制备方法 | |
| CN103284958B (zh) | 一种头孢地尼组合物颗粒剂及其制备方法 | |
| CN102247331B (zh) | 一种头孢羟氨苄咀嚼片及其制备方法 | |
| CN104546735A (zh) | 一种小儿用甲苯磺酸妥舒沙星颗粒及其制备方法 | |
| CN103919730A (zh) | 一种无水硫酸钠散剂及其制备方法 | |
| CN102018679A (zh) | 口感改善的阿奇霉素分散片及其制备方法 | |
| CN103099807A (zh) | 一种掩盖苦味和增加布洛芬溶出度的复方锌布口服组合物 | |
| CN112545996A (zh) | 一种头孢类颗粒剂及其制备方法 | |
| CN105496984A (zh) | 一种质量稳定的头孢克肟胶囊及其制备方法 | |
| CN104188920A (zh) | 托吡酯颗粒剂及其制备方法 | |
| CN103202972B (zh) | 一种小儿泡腾片 | |
| CN102416162A (zh) | 一种经口腔粘膜吸收的还原型谷胱甘肽药物 | |
| CN109200119A (zh) | 用于治疗儿童呼吸道感染的茯苓精粉制剂及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 570216 Jinpan Industrial Development Zone, Haikou City, Hainan Province, USA Industrial Village 4-2 Patentee after: Aomei Pharmaceutical (Hainan) Co., Ltd. Address before: 570216 Jinpan Industrial Development Zone, Haikou City, Hainan Province, USA Industrial Village 4-2 Patentee before: Hainan Bright Future Pharmaceutical Co., Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| CP02 | Change in the address of a patent holder |
Address after: 570311 No.2, first Yaogu Road, Yaogu Industrial Park, Haikou national high tech Industrial Development Zone, Hainan Province Patentee after: Aomei Pharmaceutical (Hainan) Co., Ltd. Address before: 570216 Jinpan Industrial Development Zone, Haikou City, Hainan Province, USA Industrial Village 4-2 Patentee before: Aomei Pharmaceutical (Hainan) Co., Ltd. |
|
| CP02 | Change in the address of a patent holder |